Jupiter Neurosciences shares surge 14.16% premarket as Nugevia expands to support GLP-1 users' mitochondrial and neuroinflammatory health.

Jupiter Neurosciences (NASDAQ: JUNS) surged 14.16% in premarket trading following its announcement to expand the Nugevia™ consumer longevity product line to support users of GLP-1 weight-loss therapies. The company highlighted rising GLP-1 adoption and consumer concerns about metabolic stress and aging-related side effects, such as "Ozempic face," as key drivers for positioning Nugevia™ MND and PWR as complementary solutions. This strategic move aligns with Jupiter’s dual-engine approach of combining clinical-stage pharmaceuticals with direct-to-consumer longevity products, emphasizing mitochondrial, metabolic, and neuroinflammatory health. The initiative underscores growing demand for science-backed, pharmaceutical-grade longevity solutions amid rapid GLP-1 therapy adoption, bolstering investor confidence in the company’s market expansion and product relevance.